NCT05748093View on ClinicalTrials.gov

Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

September 1, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Cobicistat

Feasibility of pharmacokinetic boosting using cobicistat for personalized treatment strategies for osimertinib.

Trial Locations (1)

6229HX

RECRUITING

MaastrichtUMC, Maastricht

All Listed Sponsors
lead

Maastricht University Medical Center

OTHER